<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911218-0133</DOCNO><DOCID>911218-0133.</DOCID><HL>   Technology:   Immune Response Filing</HL><DATE>12/18/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B3</SO><CO>   IMNR</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><RE>CALIFORNIA (CA)NORTH AMERICA (NME)PACIFIC RIM (PRM)SOUTH CAROLINA (SC)UNITED STATES (US)</RE><LP>   SAN DIEGO -- Immune Response Corp. said it filed anapplication with the Food and Drug Administration forapproval to begin human tests of a rheumatoid arthritisvaccine.   The biotechnology concern said it hopes to begin the testsearly next year on about 20 advanced arthritis patients. Theinitial trials at a South Carolina hospital will test thevaccine's safety and patient responses to different doses,the company said.</LP><TEXT/></DOC>